A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

Clinical trial NCT03289962 · COMPLETED

Trial details

NCT number: NCT03289962
Sponsor: Genentech, Inc.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Melanoma Non-Small Cell Lung Cancer Bladder Cancer Colorectal Cancer Triple Negative Breast Cancer Renal Cancer Head and Neck Cancer Other Solid Cancers

Start date: 2017-12-21
Primary completion: 2025-07-01
Enrollment: 273

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.